| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.unichemlabs.com | |
| Market Cap | 4,184.57 Cr. | |
| Enterprise Value(EV) | 4,392.46 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.07 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 287.24 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.30 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 353.95 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 1.68 | Calculated using Price: 594.35 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 7.04 Cr. | 70,405,751 Shares |
| FaceValue | 2 | |
| About Unichem Laboratories Ltd. | ||
| Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business. | ||
| 1 Day |
|
-1.00% |
| 1 Week |
|
+4.41% |
| 1 Month |
|
+17.57% |
| 3 Month |
|
+30.14% |
| 6 Month |
|
+38.86% |
| 1 Year |
|
+50.88% |
| 2 Year |
|
+111.83% |
| 5 Year |
|
+207.59% |
| 10 Year |
|
+163.98% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 8.95 | 11.88 | -7.02 | -7.11 | -0.97 | -2.34 | 1.35 | 1.28 | -8.04 | |
| Return on Capital Employed (%) | 9.29 | 14.93 | -7.36 | -6.1 | -1.85 | -1.46 | 2.11 | 1 | -5.6 | |
| Return on Assets (%) | 6.55 | 8.79 | -5 | -5.65 | -0.81 | -1.92 | 1.1 | 1.03 | -6.22 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 868 | 954 | 1,064 | 2,680 | 2,620 | 2,531 | 2,557 | 2,618 | 2,435 | 2,408 | |
| Non Curr. Liab. | 74 | 76 | 64 | 46 | 10 | 44 | 49 | 144 | 108 | 103 | |
| Curr. Liab. | 212 | 275 | 393 | 464 | 503 | 567 | 506 | 552 | 640 | 554 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 1,153 | 1,305 | 1,521 | 3,190 | 3,133 | 3,142 | 3,112 | 3,314 | 3,183 | 3,065 | |
| Non Curr. Assets | 589 | 673 | 772 | 854 | 1,094 | 1,455 | 1,734 | 1,666 | 1,591 | 1,529 | |
| Curr. Assets | 564 | 632 | 748 | 2,336 | 2,038 | 1,686 | 1,377 | 1,645 | 1,588 | 1,536 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 1,153 | 1,305 | 1,521 | 3,190 | 3,133 | 3,142 | 3,112 | 3,314 | 3,183 | 3,065 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 1,202 | 1,333 | 698 | 815 | 1,180 | 1,104 | 1,235 | 1,270 | 1,343 | 1,675 | |
| Other Income | 21 | 19 | 6 | 61 | 98 | 91 | 50 | 48 | 39 | 31 | |
| Total Income | 1,223 | 1,352 | 703 | 875 | 1,278 | 1,195 | 1,285 | 1,317 | 1,382 | 1,706 | |
| Total Expenditure | -1,101 | -1,169 | -739 | -946 | -1,264 | -1,155 | -1,144 | -1,197 | -1,389 | -1,584 | |
| PBIDT | 122 | 183 | -36 | -71 | 15 | 40 | 141 | 120 | -7 | 122 | |
| Interest | -3 | -3 | -3 | -8 | -8 | -8 | -5 | -6 | -17 | -24 | |
| Depreciation | -41 | -39 | -44 | -51 | -67 | -82 | -84 | -91 | -113 | -116 | |
| Taxation | -2 | -29 | 12 | -3 | 34 | -12 | -17 | 11 | -26 | -2 | |
| Exceptional Items | -4 | -39 | 34 | ||||||||
| PAT | 75 | 108 | -71 | -133 | -26 | -60 | 34 | 33 | -202 | 15 | |
| Minority Interest | |||||||||||
| Share Associate | 0 | ||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 75 | 108 | 109 | 2,545 | -24 | -60 | 34 | 33 | -202 | 15 | |
| Adjusted EPS | 8 | 12 | 12 | 362 | -3 | -9 | 5 | 5 | -29 | 2 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 87 | 78 | 112 | 68 | -112 | -328 | 20 | 33 | -260 | -85 | |
| Cash Fr. Inv. | 36 | -52 | -85 | -128 | 1,648 | -286 | -36 | -74 | 102 | 203 | |
| Cash Fr. Finan. | -95 | -51 | -33 | 59 | -881 | -2 | -62 | -121 | 191 | -81 | |
| Net Change | 28 | -25 | -7 | 0 | 655 | -616 | -78 | -162 | 34 | 36 | |
| Cash & Cash Eqvt | 52 | 27 | 20 | 11 | 666 | 197 | 232 | 77 | 109 | 184 |
|
Mon, 08 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018 Unichem Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
Wed, 03 Apr 2024
Disclosure under SEBI Takeover Regulations Harish Kamath, For and on behalf of Ipca Laboratories Ltd. has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |
|
Mon, 01 Apr 2024
Disclosure under SEBI Takeover Regulations Unichem Laboratories Limited??has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India??(Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |
| Wed, 24 Apr 2024 |
Close Within 52 Week High Zone
|
High Increase in 1 Month
|
High Increase in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
